{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T03:17:38Z","timestamp":1779333458982,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["JNM-85075"],"award-info":[{"award-number":["JNM-85075"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association,","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.omtn.2019.02.003","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T02:51:40Z","timestamp":1550199100000},"page":"12-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["RNA-Based Therapy Utilizing Oculopharyngeal Muscular Dystrophy Transcript Knockdown and Replacement"],"prefix":"10.1016","volume":"15","author":[{"given":"Aida","family":"Abu-Baker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawwaf","family":"Kharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Perreault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alanna","family":"Grant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud","family":"Shekarabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Maios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Dona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Neri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick A.","family":"Dion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Varin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy A.","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2019.02.003_bib1","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.nbd.2004.09.021","article-title":"Transgenic expression of an expanded (GCG)13 repeat PABPN1 leads to weakness and coordination defects in mice","volume":"18","author":"Dion","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.omtn.2019.02.003_bib2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/1531-8249(200011)48:5<798::AID-ANA16>3.0.CO;2-U","article-title":"PABP2 polyalanine tract expansion causes intranuclear inclusions in oculopharyngeal muscular dystrophy","volume":"48","author":"Shanmugam","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2019.02.003_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00692226","article-title":"Nuclear inclusions in oculopharyngeal dystrophy","volume":"49","author":"Tom\u00e9","year":"1980","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.omtn.2019.02.003_bib4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng0298-164","article-title":"Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy","volume":"18","author":"Brais","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2019.02.003_bib5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/hmg\/4.3.429","article-title":"The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13","volume":"4","author":"Brais","year":"1995","journal-title":"Hum. Mol. Genet."},{"issue":"Suppl 1","key":"10.1016\/j.omtn.2019.02.003_bib6","doi-asserted-by":"crossref","first-page":"S06","DOI":"10.21035\/ijcnmh.2016.3(Suppl.1).S06","article-title":"Current targeted therapeutic strategies for oculopharyngeal muscular dystrophy: from pharmacological to RNA replacement and gene editing therapies","volume":"3","author":"Abu-Baker","year":"2016","journal-title":"Int. J. Clin. Neurosci. Ment. Health"},{"key":"10.1016\/j.omtn.2019.02.003_bib7","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1093\/hmg\/ddg293","article-title":"Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy","volume":"12","author":"Abu-Baker","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2019.02.003_bib8","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/hmg\/ddn109","article-title":"Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1","volume":"17","author":"Catoire","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2019.02.003_bib9","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1212\/WNL.0000000000005942","article-title":"Valproic acid is protective in cellular and worm models of oculopharyngeal muscular dystrophy","volume":"91","author":"Abu-Baker","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2019.02.003_bib10","doi-asserted-by":"crossref","first-page":"e821","DOI":"10.1038\/cddis.2013.342","article-title":"Lithium chloride attenuates cell death in oculopharyngeal muscular dystrophy by perturbing Wnt\/\u03b2-catenin pathway","volume":"4","author":"Abu-Baker","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omtn.2019.02.003_bib11","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/hmg\/10.21.2341","article-title":"Oligomerization of polyalanine expanded PABPN1 facilitates nuclear protein aggregation that is associated with cell death","volume":"10","author":"Fan","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2019.02.003_bib12","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1600-0854.2005.00315.x","article-title":"Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy","volume":"6","author":"Abu-Baker","year":"2005","journal-title":"Traffic"},{"key":"10.1016\/j.omtn.2019.02.003_bib13","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1093\/hmg\/ddi395","article-title":"Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells","volume":"14","author":"Wang","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2019.02.003_bib14","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1093\/hmg\/ddp101","article-title":"Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in\u00a0vivo","volume":"18","author":"Chartier","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2019.02.003_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/hmg\/ddi432","article-title":"Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody","volume":"15","author":"Verheesen","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2019.02.003_bib16","doi-asserted-by":"crossref","first-page":"34ra40","DOI":"10.1126\/scitranslmed.3000723","article-title":"Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy","volume":"2","author":"Davies","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2019.02.003_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/hmg\/ddi422","article-title":"Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy","volume":"15","author":"Davies","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2019.02.003_bib18","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/nm1242","article-title":"Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice","volume":"11","author":"Davies","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2019.02.003_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/mt.2013.155","article-title":"Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a phase I\/IIa clinical study","volume":"22","author":"P\u00e9ri\u00e9","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2019.02.003_bib20","doi-asserted-by":"crossref","first-page":"14848","DOI":"10.1038\/ncomms14848","article-title":"PABPN1 gene therapy for oculopharyngeal muscular dystrophy","volume":"8","author":"Malerba","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2019.02.003_bib21","doi-asserted-by":"crossref","first-page":"12263","DOI":"10.1074\/jbc.M109633200","article-title":"Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy","volume":"277","author":"Bao","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2019.02.003_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/emmm.201000109","article-title":"Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy","volume":"3","author":"Barbezier","year":"2011","journal-title":"EMBO Mol. Med."},{"issue":"16 Suppl","key":"10.1016\/j.omtn.2019.02.003_bib23","article-title":"Intravenous Trehalose Improves Dysphagia and Muscle Function in Oculopharyngeal Muscular Dystrophy (OPMD): Preliminary Results of 24 Weeks Open Label Phase 2 Trial (S28.004)","volume":"86","author":"Argov","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2019.02.003_bib24","first-page":"11","article-title":"Antisense inhibition: oligonucleotides, ribozymes, and siRNAs","volume":"106","author":"Zhang","year":"2005","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.omtn.2019.02.003_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1566523052997541","article-title":"Synthetic hammerhead ribozymes as therapeutic tools to control disease genes","volume":"5","author":"Citti","year":"2005","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.omtn.2019.02.003_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cbpa.2017.09.017","article-title":"Structure-based mechanistic insights into catalysis by small self-cleaving ribozymes","volume":"41","author":"Ren","year":"2017","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.omtn.2019.02.003_bib27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2174\/138920210793175895","article-title":"MicroRNA: Biogenesis, Function and Role in Cancer","volume":"11","author":"Macfarlane","year":"2010","journal-title":"Curr. Genomics"},{"key":"10.1016\/j.omtn.2019.02.003_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.trsl.2011.02.001","article-title":"MicroRNAs: miRRORS of health and disease","volume":"157","author":"Montano","year":"2011","journal-title":"Transl. Res."},{"key":"10.1016\/j.omtn.2019.02.003_bib29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2019.02.003_bib30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrg3965","article-title":"Towards a molecular understanding of microRNA-mediated gene silencing","volume":"16","author":"Jonas","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omtn.2019.02.003_bib31","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1093\/nar\/gkv1111","article-title":"Automated design of hammerhead ribozymes and validation by targeting the PABPN1 gene transcript","volume":"44","author":"Kharma","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2019.02.003_bib32","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1212\/WNL.55.9.1267","article-title":"Oculopharyngeal MD among Bukhara Jews is due to a founder (GCG)9 mutation in the PABP2 gene","volume":"55","author":"Blumen","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2019.02.003_bib33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.nmd.2004.10.012","article-title":"(GCG)11 founder mutation in the PABPN1 gene of OPMD Uruguayan families","volume":"15","author":"Rodr\u00edguez","year":"2005","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2019.02.003_bib34","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/bjo.2007.131482","article-title":"Two different PABPN1 expanded alleles in a Mexican population with oculopharyngeal muscular dystrophy arising from independent founder effects","volume":"92","author":"Rivera","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.omtn.2019.02.003_bib35","first-page":"376","article-title":"[Haplotype Analysis of Oculopharyngeal Muscular Dystrophy (OPMD) Locus in Yakutia]","volume":"52","author":"Marusin","year":"2016","journal-title":"Genetika"},{"key":"10.1016\/j.omtn.2019.02.003_bib36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/mt.2008.231","article-title":"Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in\u00a0vitro and in\u00a0vivo","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2019.02.003_bib37","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/hmg\/ddm382","article-title":"Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation","volume":"17","author":"Davies","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2019.02.003_bib38","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1016\/S0021-9258(18)53864-3","article-title":"Mammalian poly(A)-binding protein II. Physical properties and binding to polynucleotides","volume":"268","author":"Wahle","year":"1993","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2019.02.003_bib39","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.nbd.2007.02.004","article-title":"Soluble expanded PABPN1 promotes cell death in oculopharyngeal muscular dystrophy","volume":"26","author":"Messaed","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.omtn.2019.02.003_bib40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/excr.1994.1235","article-title":"Immunodetection of poly(A) binding protein II in the cell nucleus","volume":"214","author":"Krause","year":"1994","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.omtn.2019.02.003_bib41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","article-title":"RNA therapeutics: beyond RNA interference and antisense oligonucleotides","volume":"11","author":"Kole","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2019.02.003_bib42","doi-asserted-by":"crossref","first-page":"14258","DOI":"10.1073\/pnas.1109522108","article-title":"Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins","volume":"108","author":"Li","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2019.02.003_bib43","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/hmg\/7.10.1649","article-title":"Ribozymes as therapeutic tools for genetic disease","volume":"7","author":"Phylactou","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2019.02.003_bib44","first-page":"9050","article-title":"Identifying proteins that bind to specific RNAs - focus on simple repeat expansion diseases","volume":"44","author":"Jazurek","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2019.02.003_bib45","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1007\/s00018-016-2284-0","article-title":"Modeling simple repeat expansion diseases with iPSC technology","volume":"73","author":"Jaworska","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omtn.2019.02.003_bib46","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/mt.2013.144","article-title":"Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease","volume":"21","author":"Costa","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2019.02.003_bib47","first-page":"1","article-title":"Maintenance of C. elegans","volume":"2006","author":"Stiernagle","year":"2006","journal-title":"WormBook"},{"key":"10.1016\/j.omtn.2019.02.003_bib48","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cell.2006.04.036","article-title":"C.\u00a0elegans SIR-2.1 interacts with 14-3-3 proteins to activate DAF-16 and extend life span","volume":"125","author":"Berdichevsky","year":"2006","journal-title":"Cell"}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253119300332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253119300332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:23:49Z","timestamp":1761873829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253119300332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":48,"alternative-id":["S2162253119300332"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2019.02.003","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA-Based Therapy Utilizing Oculopharyngeal Muscular Dystrophy Transcript Knockdown and Replacement","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2019.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}